Pharmacokinetics of Lopinavir in HIV Type-1-Infected Children Taking the New Tablet Formulation Once Daily
Antiviral Therapy2008Vol. 13(8), pp. 1087–1090
Citations Over TimeTop 25% of 2008 papers
Michiel van der Flier, Gwenda Verweel, Linda C. van der Knaap, Petronette van Jaarsveld, Gertjan J. Driessen, Manon van der Lee, Nico G. Hartwig, David M. Burger
Abstract
The tablet formulation could probably result in improved lopinavir dosing and increases the feasibility of once-daily lopinavir/ritonavir-based regimens in children.
Related Papers
- → Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019(2020)39 cited
- → Gemfibrozil Concentrations Are Significantly Decreased in the Presence of Lopinavir-Ritonavir(2009)27 cited
- → Lopinavir/Ritonavir Pharmacokinetic Profile: Impact of Sex and Other Covariates Following a Change From Twice‐Daily to Once‐Daily Therapy(2007)17 cited
- PHARMACOKINETIC EXPOSURE AND VIROLOGIC RESPONSE IN HIV-1 INFECTED PREGNANT WOMEN TREATED WITH LOPINAVIR/RITONAVIR: AIDS CLINICAL TRIALS GROUP PROTOCOL A5153S: A SUBSTUDY TO A5150.(2015)
- → Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir(2012)3 cited